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Abstract. The treatment of advanced gastric cancer
remains challenging as the outcomes achieved with surgery
alone or adjuvant or neoadjuvant chemotherapy and
radiotherapy are poor. New treatment strategies are
emerging and being tested in advanced gastric cancer.
Vascular endothelial growth factor (VEGF) inhibitors have
been confirmed as important therapeutic agents in
randomised clinical trials in multiple solid tumour settings.
Until now, results of phase II and phase III clinical trials of
anti-angiogenic agents on gastric cancer have been
relatively modest, with moderate improvement in overall
survival. The effects of these drugs are limited due to
development of resistance to them and the increased risk of
tumour invasion and metastasis. If we are to optimise or
develop combination regimens for advanced gastric cancer
with VEGF inhibitors that build on their efficacy, it is
critical to identify and validate biomarkers in order to
enable selection of those patients who are prone to benefit
and monitor their response to the drugs. Validated
biomarkers can help to further personalise VEGF inhibitors
and dosage determination for advanced or metastatic
gastric cancer, particularly as these drugs can be toxic and
expensive. Although no biomarker is validated for routine
use for this purpose, several candidates are currently under
investigation. In this review, we aim to give an overview of
the recent developments in biomarkers for anti-angiogenic
therapy in gastric cancer tumour angiogenesis.
Gastric cancer affects more than one million people per year
worldwide (1). Despite advancement in early detection, most
patients with gastric cancer present with advanced stages and
metastasis at the time of diagnosis (2). Currently, surgery
removal remains the only therapeutic option for the disease.
However, management of advanced gastric cancer is shifting
from standard surgical resection, adjuvant and neoadjuvant
regimens to combination strategies with targeted therapies,
including anti-angiogenic therapies [especially vascular
endothelial growth factor (VEGF) inhibitors] (3). 
A biomarker can act as a diagnostic indicator that is
objectively measured and evaluated for a biological of
pathogenic process or of pharmacological response to a
therapeutic intervention (2). Targeted therapies theoretically
target essential element(s) of signaling pathways known to
be involved in tumorigenesis. For targeted therapies,
identifiable corresponding biomarkers related to those
pathways that help guide treatment are generally required, as
general parameters developed for monitoring cytotoxic
therapies may not apply. In gastric cancer, well-recognised
and validated biomarkers for diagnosis and treatment
monitoring include the carcinoembryonic antigen (CEA), and
carbohydrate antigens (CA). These markers exhibit defined
criteria of disease response and progression based on
changes in their serum levels, although the appropriateness
of instigating treatment by such biomarker-defined
progression alone has recently been challenged (4). In
addition, pharmacodynamic biomarkers are used in the
development of targeted therapies to indicate target
modulation (proof of mechanism) and define the optimal
biological dose in early-phase clinical trials.
Based on the simplified assumption of the homogeneity of
vasculature, anti-angiogenic therapy targeting tumour
vasculature has been designed to apply to most solid tumour
types, irrespective of the genetic makeup of each tumour.
Since the clinical development of anti-angiogenic agents has
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not been biomarker-based, the overall efficacy of current
anti-angiogenic drugs has suffered greatly from the practice
of indiscriminately applying those medicines to all patients
with cancer. The same tumour type responds differently to
the same anti-angiogenic therapy. For example, in two
clinical trials of bevacizumab (3) and ramucirumab (5), a
subset of patients with gastric cancer responded transiently,
whereas another group had essentially no response.
Bevacizumab (Avastin®) is a monoclonal antibody targeting
VEGF, whereas ramucirumab is another human monoclonal
antibody selectively binding to the extracellular region of
VEGF receptor-2 (VEGFR2). These findings raise the
importance of: i) predicting whether a patient will benefit
from an anti-angiogenic agent, and monitoring its efficacy or
the development of resistance to it; and ii) exclusion of
patients who do not response to anti-angiogenic therapy, in
order to avoid the toxicities and cost of these drugs; and iii)
the development of new anti-angiogenic strategies in which
current anti-angiogenic drugs have failed in unselected
populations. 
At the point in the development of VEGF inhibitors for
cancer treatment, the complexity of tumour angiogenesis,
with the various intrinsic/extrinsic regulatory and adaptive
mechanisms suggest that multiple and different biomarkers
are essential for comprehensively examining angiogenesis
and its therapeutic response. There is an urgent need to
identify related biomarkers (e.g. predictive, pharmacological
and surrogate response), and in particular, to discriminate
them from prognostic biomarkers which inform on the
progression of disease irrespective of treatment. The focus
of this review is to report on recent advances in these areas,
where many hypothesis-driven biomarker candidates have
been tested in experimental models and clinical studies, even
though to date none has been validated for routine use in
patients bearing advanced gastric cancer. We arbitrarily
clustered them into two groups: systemic and local (in situ)
biomarkers for the sake of discussion. 
Systemic Biomarkers
Hypertension. The rapid induction of hypertension in a
significant minority of patients appears to be a classic adverse
effect of VEGF inhibitors. The results obtained from the
RAINBOW trial, which began in 2010 and involved 665
patients with advanced gastric cancer, showed hypertension
occurring at a higher rate in patients treated with
ramucirumab, a human antibody targeting VEGFR2, in
combination with paclitaxel regimen (5). The level of
hypertension is dose-dependent, although the exact
mechanisms behind it might be multifactorial and remain to
be elucidated. One plausible explanation is that VEGF
signaling regulates nitric oxide synthesis (6). Inhibition of
VEGF signaling causes a reduction in the synthesis of nitric
oxide, increasing vasoconstriction and therefore hypertension.
Nevertheless, it provides the rationale for using a change in
blood pressure as a surrogate system biomarker to evaluate
successful inhibition of VEGF signalling. For instance, it may
be practically appropriate to increase the dose of VEGF
inhibitors, if tolerated, until hypertension is observed. The
report of a multicentre phase III trial including 355 patients
bearing advanced gastric or gastro-oesophageal junction
adenocarcinoma seems to corroborate this hypothesis (7). It
was the first to report that a single VEGF inhibitor can exert
survival benefit in patients with advanced gastric cancer. The
rates of hypertension were higher in the ramucirumab-treated
group than the placebo-treated group, whereas the other
adverse effects occurred in both groups at similar rates (7). 
Circulating biomarkers. Circulating biomarkers of VEGF
signalling: Circulating molecules associated with angiogenesis
are the most accessible potential biomarkers. Blood sampling is
convenient and less invasive than tissue sampling, allowing
multiple samples to be taken. Techniques of isolation are
quantitative, simple and relatively inexpensive, while
concentration measurement is quantitative. These markers
consist of circulating angiogenic factors, cell surface receptors,
adhesion molecules, circulating proteins or peptides,
downstream signalling molecules and even cells (8, 9). 
Serum VEGF levels are thought to reflect the activity of
VEGF-mediated tumour angiogenesis and an increasing
circulating VEGF level has been shown to be an adverse
prognostic factor in gastric cancer (10). The majority of
clinical trials that have evaluated VEGF inhibitors in cancer
treatment have involved investigation of circulating VEGFA
(plasma or serum), although urine measurement has been
studied (11, 12), even though the effects of VEGF inhibitors
on gastric cancer are controversial and inconclusive. For
example, one study demonstrated that VEGF inhibition using
bevacizumab combined with chemotherapy might be a
promising option for patients with metastatic or unresectable
gastro-oesophageal junction adenocarcinoma (13), whereas
a randomised phase III study of bevacizumab plus
capecitabine failed to provide evidence of the efficacy of
bevacizumab in gastric cancer (3). 
Correlation between circulating VEGFA levels and
response to VEGF inhibitor treatment has also been
examined in patients with gastric cancer. However, the
results were complex and inconclusive. Of note, in patients
with extensive-stage gastric cancer patients from non-Asian
regions who received bevacizumab in addition to
chemotherapy agents, baseline levels of VEGFA and
neuropilin-1 (NRP1) predicted bevacizumab effect in terms
of overall survival. Patients who had high baseline levels of
both VEGFA and NRP1 had a higher risk of progression to
death compared to those who had a low baseline of these
(14). Thus, a hypothesis would be that the change in serum
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VEGF levels induced by VEGF inhibition might predict
patient benefit. However, patients with Asian origin tended
to have a low baseline of serum VEGFA and those with high
VEGFA levels did not respond to the VEGF inhibitor.
However, additional similar trials with more patients might
help us clarify the apparent race-based discrepancy. One
possible reason is that the high serum VEGF level in the
patients from the two populations come from different
sources. One study conducted using analysis of VEGFA
expression in Japanese patients with advanced gastric cancer
(both in situ lesions and peritoneal metastases) showed that a
significant fall in serum VEGFA level was only observed in
patients with peritoneal metastases treated regionally
(peritoneally) with bevacizumab (15). That study indicated
that malignant and metastatic peritoneal ascites may be the
primary source of VEGFA for gastric cancer, and the
antibody neutralizing VEGFA reduced its entry into
circulation, resulting in a low blood concentration, thereby
enhancing the efficacy of systemically administering VEGF
inhibitors by removing ascites before the treatment. 
In addition to VEGFA, other members of the VEGF family
exhibit differential effects on gastric cancer vasculature.
Patients with high expression of both VEGFC have a worse
prognosis, with higher microvessel density (MVD), local
invasion and metastasis (16), while VEGFB does not seem
to be involved in the progression of gastro-oesophageal
cancer (17), and VEGFD is mainly responsible for
lymphogenesis in gastric cancer (18). Most consistently,
placenta growth factor (PlGF) expression levels are
significantly higher in gastric cancer (19). Intriguingly, PlGF
levels are increased in patients with different types of cancer
treated with VEGF inhibitors, irrespective of inhibitory
mechanisms (20). This finding led to the hypothesis of a
critical role of PlGF in tumour vasculature rescue and the
development of resistance to VEGF inhibitors, that need to
be further examined. Of interest, changes in PlGF levels may
serve as pharmacodynamic systemic biomarkers for VEGF
inhibition in gastric cancer treatment.
Various alternative strategies inhibiting VEGF signaling
include targeting VEGFRs. Several small-molecule inhibitors
have been investigated in combination with chemotherapy
agents in patients with advanced gastric cancer. For instance,
sunitinib and sorafenib are designed to target the binding of
ATP to the tyrosine domain of VEGFRs in a reversible
manner. Unfortunately, both drugs exert off-target effects due
to lack of specificity. Recently a specific VEGFR2 tyrosine
kinase inhibitor, namely apatinib, replaced two
aforementioned drugs in clinical trials for gastric cancer.
Ramucirumab is an example of alternative method of anti-
VEGFR strategy; it is a fully humanized monoclonal
antibody targeting the VEGF-binding domain of VEGFR2.
Cediranib is a highly potent inhibitor targeting both VEGFR2
and VEGFR1. However, none of these receptor tyrosine
kinases have yet been evaluated as molecular biomarkers of
response in gastric cancer, at least they have not yet been
formally reported. 
Apart from the full-length membrane receptors, soluble
VEGFRs (sVEGFRs) are presented in serum as the result of
alternative splicing or membrane shedding (21). sVEGFR1 has
a high affinity for VEGFA, leading to development of
sVEGFR1 in patients with gastric cancer as endogenous
VEGFA inhibitor (22). The circulating sVEGFR1 level is
being explored as a predictive biomarker of response to
VEGFA inhibitors in cancer, including gastric cancer (14).
One hypothesis is that patients with cancer with pre-existing
high levels of sVEGFR1 are prone to development of
resistance to bevacizumab. sVEGFR2 is abundant in blood
circulation. A clinical study showed that foretininb, an oral
VEGFR2 inhibitor, induced a significant decrease in serum
sVEGFR2 in patients with metastatic gastric cancer (23). The
presence of sVEGFR2 has been associated with improved
outcome in other solid types of tumour, but its value as a
predictive or pharmacodynamic biomarker for VEGF
inhibition in patients with gastric cancer is currently unknown.
To date, a circulating biomarker signature for anti-VEGF
treatment of solid types of cancer has been recognized to
include an increase in serum VEGFA and PlGF, and a
reduction in soluble VEGFRs. We propose that there is a
necessity for expansion in the evaluation of this biomarker
signature to gastric cancer clinical trials involving VEGFR
inhibitors since this biomarker signature represents the
largest repertoire of VEGF signalling targeted by VEGFR
inhibitors. 
Circulating cells: Circulating endothelial cells (CECs) are
believed to be derived from the turnover of blood vessel
walls, either of the mature vessel ortumour vasculature. A
sub-population of CECs originating from the bone marrow
that have a progenitor-like phenotype are called circulating
endothelial progenitor cells and contribute to vascularization
of late-stage cancer. Healthy adults have 1-20 CECs per
millilitre of their peripheral blood and the changes in the
number of CECs significantly increases in patients with
advanced gastric cancer (24). After successful chemotherapy,
the number regresses to normal levels in patients with
advanced gastric cancer and is a predictive biomarker (25).
However, results of studies evaluating changes in CECs and
circulating endothelial progenitor cells in patients with
cancer receiving VEGF inhibitors are controversial and
inconclusive due to a significant diversity of techniques
found in their isolation, as well as the lack of a clear
consensus on antigen profiling. In general, the CEC number
tends to decrease upon treatment with VEGF inhibitors in
patients with cancer (26, 27). Interestingly, one study showed
that in patients with gastrointestinal stromal tumours treated
with sunitinib, a transient increase in CECs was associated
with a better outcome (28).
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Other notable circulating cells are circulating tumour cells
(CTCs) that are derived from metastatic cancer cells or even
cancerous stem cells. Efforts have been made to detect,
isolate and enumerate CTCs. Mesenchymal epithelial
transition factor for cancer (c-MET) is a receptor tyrosine
kinase encoded by the MET oncogene and identified as a
prognostic marker in gastric cancer (29). Interestingly, c-
MET has been used to capture and identify circulating gastric
cancer cells (30). Higher levels of c-MET positive circulating
gastric cancer cells were only detected in patients with
gastric cancer. We speculate here that this approach may be
useful in follow-up of patients who are under anti-VEGF
therapy.
Other circulating biomarkers. Recently, microRNAs
(miRNAs), possessing excellent stability in the bloodstream,
have been detected in the serum or plasma from patients with
a variety of solid tumour types. In gastric cancer, some
miRNAs, including miRNA-378, -451, 486, -17-5p, -21,
106a, -106b, 199a-3p and -200c displayed higher serum
expression (31-33). Among them, high serum levels of
miRNA-199a-3p and -200c were significantly associated
with gastric cancer and declined after gastrectomy (34, 35).
Energy metabolism changes are one of the cancerous
hallmarks (36). Energy metabolism reprogramming results in
increased glycolytic activity and reduced mitochondrial
respiration, even in the presence of oxygen, a phenomenon
called the Warburg effect (37). As a result, change in
circulating mitochondrial DNA has emerged as a potential
biomarker for gastric cancer (38). 
Circulating cell-free DNA (cfDNA) is released into blood
circulation during tumour metastasis, necrosis, and apoptosis
(39). A decrease in cfDNA has been associated with reduced
tumour size on treatment. A clinical study demonstrated the
possibility of usage of cfDNA as a sensitive predictive
biomarker to assess tumour burden and residual tumour after
treatment (40). The authors found that changes in the level
of cfDNA are significantly correlated with gastric cancer
development. 
Annexin A2 (ANXA2) has been found to be involved in
tumour growth, invasion, angiogenesis and metastasis in
autocrine and paracrine manners in patients with gastric
cancer (41). ANXA2 belongs to annexin family of calcium
and phospholipid-binding proteins that regulate a range of
molecular and cellular activities during carcinogenesis.
Clinical investigation revealed that an elevating serum level
of ANXA2 in patients with gastric cancer was significantly
associated with the development of chemoresistance (42).
Unfortunately, these circulating biomarkers have not been
incorporated into the clinical evaluation of VEGF inhibitors
in patients with gastric cancer. However, it is now important
that their potential as biomarkers for anti-VEGF therapy for
gastric cancer treatment is researched.
Genetic biomarkers. Genetic studies have suggested that
inherited variations in genes related to angiogenesis, at
least partially, cause the documented mixed response to
VEGFA inhibitors. Few studies have reported an
association between clinical outcome of gastric cancer and
single-nucleotide polymorphisms (SNPs) in genes for
VEGFA. When patients with advanced gastric cancer were
treated with oxaliplatin, 5-fluorouracil (5-FU), and
leucovorin (FOLFOX), SNP analysis demonstrated that
VEGFA -634G/G gene polymorphism was related to higher
serum VEGFA levels (43). Unfortunately, no study has
reported that patients with VEGFA -634G/G genotype
attained a better response rate and progression-free survival
(PFS) regarding VEGF inhibitors. Interestingly, patients
bearing advanced colorectal cancer with VEGF -A634G/C
genotype had a significant response rate to the regimen of
5-FU, irinotecan and bevacizumab (44). Moreover, patients
with recurrent ovarian cancer with VEGFA +937T
polymorphism C/T genotype had a longer PFS when treated
chemotherapy with bevacizumab (45), while VEGFA
2578AA genotype was significantly associated with the
response rate in patients with advanced breast cancer, with
a superior median overall survival after receiving paclitaxel
combined with bevacizumab (46). 
More recently, the effects of multiple genetic variants on
the efficacy of bevacizumab were evaluated by a meta-
analysis of six randomized phase III trials in colorectal,
pancreatic, lung, renal, breast, and gastric cancer (9). The
study identified that three genetic variants in VEGFC,
endothelial PAS domain-containing protein 1 (EPAS1) and
interleukin 8 receptor α (IL8RA) were predictive of
bevacizumab treatment outcome. These variants were
significantly associated with PFS in bevacizumab-treated
patients (p<0.05). Interestingly, one variant in VEGFA had
predictive value in bevacizumab-treated patients but failed to
reach significance in the interaction analysis (p=0.091).
Furthermore, the VEGFC variant does not affect VEGFC
expression and its predictive role in bevacizumab treatment is
not yet clear. In contrast, EPAS1 (hypoxia-induced factor-1
α) is a well-established regulator of angiogenesis as an
oxygen-sensitive transcription factor in response to hypoxic
stress conditions (47). The IL8RA variant has been reported
to regulate angiogenesis independently of VEGFA signalling
by altering chemokine (C-X-C motif) receptor 1 (CXCR1)
expression. In addition, the altered expression of CXCR1
was shown to activate a particular immune response, which
could exert a synergistic effect on outcome of bevacizumab
treatment (48). In terms of a biomarker for anti-VEGF
therapy in patients with gastric cancer, these genetic variants
should be explored in further prospective gastric cancer
trials, and it will be important to define the
structure–functional relationships for particular variants
associated with best or worst outcome.
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Local (in situ) Biomarkers
Tissue-based biomarkers. As emerged from the AVAGAST
trial, intratumoral levels of VEGFA in patients have so far not
been shown to predict a value for bevacizumab treatment in
patients with gastric cancer (14), although its positive impact
on overall survival has been reported (49). For most types of
solid tumours, the only way to make a definitive diagnosis is to
examine a tumour specimen, whenever available, for example,
when biopsies can be performed or when tissues are obtained
at surgery. However, there are limitations to identifying tissue-
based biomarkers related to the effects of anti-VEGF therapy
because of invasiveness and the difficulty in standardizing
immunohistochemical analysis. The conclusion from
AVAGAST, a recent phase III trial of bevacizumab in
combination with chemotherapy in advanced gastric cancer, are
exemplary of such limitations (14). For instance, different
sample methods such as slides or blocks confounded the
interpretation, leading to inconsistent results. Loss of
immunoreactivity more often happens to paraffin-embedded
tumour tissue stored on slides rather than blocks. Moreover, the
main pitfalls of applying immunohisto-chemistry as a
quantitative analysis without the consensus of standardized
tests include pre-analytic tissue processing and subjective
scoring. Given the disappointing results so far, and considering
the limitations of tissue biomarker evaluation, tissue-based
VEGFA does not appear to be a promising biomarker unless
the above limitations are improved considerably. 
Tumour MVD has often been evaluated as a biomarker
relating to blood vessel formation within tumours and was
first reported in breast cancer more than two decades ago
(50). Increased MVD has been associated with poor
prognosis in gastric cancer (51), although there are some
conflicting reports (52). In a study of VEGF inhibition in a
gastric cancer model, decreased tumour growth was
associated with a reduction in MVD on serial tumour
biopsies from gastric cancer xenografts in animals (53). The
translational component from this pre-clinical study was that
a decrease in high basal MVD was significantly associated
with the response to bevacizumab in the bevacizumab-
sensitive models, whereas no change was detected in the
bevacizumab-insensitive models at any time point after
treatment. Most interestingly, the decrease of MVD in
response to the antitumour activity of bevacizumab was
detected before the reduction of tumour volume.
Unfortunately, no correlation between the basal MVD and
the response to bevacizumab was identified in the landmark
phase III trial of bevacizumab in addition to capecitabine/5-
FU in advanced gastric cancer (14).
Imaging biomarkers. Anti-VEGF agents are primarily
cytostatic and functional imaging techniques can measure
changes in tumour vasculature or metabolic process
associated with angiogenesis. Endoscopic imaging can
monitor the pre-neoplastic, pre-malignant, and cancerous
stages in gastrointestinal lesions. However, conventional
optical white-light endoscopy (WLE) appears to be of limited
use in evaluating gastrointestinal vasculature. A major
challenge in the screening of gastric tumour vasculature is the
large surface area of the gastric lumen and the need to
perform image-enhanced wide-field imaging that can
highlight small abnormal mucosal areas. Several new imaging
techniques to overcome limitations of WLE have emerged,
including probe-based confocal laser endomicroscopy (pCLE)
(54), narrow-band imaging and magnification endoscopy
(NBI) (55), autofluorescence imaging (AFI) (56) and i-Scan
(57). A recent study demonstrated that pCLE seems to hold
the greatest promise as a prognostic and predictive biomarker
for VEGF inhibitors in patients with gastrointestinal cancer
(58-60). In pCLE, a confocal scanning microscope is
integrated into a conventional flexible endoscope, providing
cellular and subcellular resolution in the horizontal plane of
the targeted tissues. By using fluorescein isothiocyanate-
labelled antibodies against angiogenesis-related proteins, such
as VEGFA, VEGFRs or cluster of differentiation 31(CD31)
(an endothelial-specific antigen), pCLE is capable of in vivo
assessment of the morphological alterations and the abnormal
microvasculature of the (mucosa) gastric cancer. By
combined the morphological pCLE data with the histological
data, an arbitrary angiogenesis scale (Cannizzaro-Spessoto
scale) has been proposed to reflect the increased intratumoral
tortuous and large vessels, fluorescein leakage, and defect
flux (58). At the moment, pCLE use has been limited to a
small number of specialist centres because of the requirement
for well-trained endoscopists (61). We firmly believe that new
design strategies incorporating with these new imaging
techniques will significantly increase biomarker-driven
clinical trials of VEGF inhibitors in patients with
gastrointestinal cancer.
In spite of the use of endoscopy, endomicroscopy is a
most useful diagnostic tool for gastrointestinal lesions;
repeated endoscopy can cause discomfort and other side-
effects. Capsule endoscopy (CE) was originally designed for
relatively non-invasive measurement of bowel movement
without causing pain to the patient (62). The latest
development in CE has led to novel wireless capsule video
endoscopy (WCVE), consisting of CE with a camera,
battery, and attached LED lamps for illumination (63). After
being swallowed, the WCVE device emits a radio signal to
an external meter. A video is recorded at a rate of two frames
per second as the WCVE device travels along the digestive
track. Once downloaded, specialists examine the video to
visualize the zone of interest and lesions. To our knowledge,
there is no study yet reporting the use of WCVE for studying
tumour vasculature in gastrointestinal cancer. In our opinion,
however, one of the greatest advantages of WCVE is that it is
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much less invasive, without need for hospitalisation and
expert support through the process. Thus, WCVE will be
very useful for monitoring the effects of VEGF inhibitors
administered to patients with gastrointestinal cancer in
clinical trials of VEGF inhibitors. 
Summary
Many of the biomarker studies described above are
exploratory and observational. There is considerable
heterogeneity between different studies, assays and
outcomes. Therefore, high-quality biomarker studies should
be conducted to test candidate biomarkers in optimised
randomised clinical trial designs, particularly some of the
above-mentioned biomarkers that have not been evaluated in
patients with gastric cancer receiving VEGF inhibitors. We
believe that a specific group of different biomarkers (i.e. a
signature) may be needed for each VEGF inhibitor. Since
neoadjuvant chemotherapy followed by delayed primary
surgery does not benefit overall survival in patients with
gastric cancer (64), identification of biomarkers of early
response to VEGF inhibitors is difficult. Nevertheless,
identifying a proper biomarker signature for currently
approved VEGF inhibitors is a priority.
One major challenge for the interpretation of biomarker
studies is to make a distinction between prognostic and
predictive values from a vast amount of data. Predictive
biomarkers in the first-line setting may also not be suitable
for patients with relapse. Another difficulty is determining
whether a given effect is the result of anti-angiogenic activity
or of affecting other oncogenic functions. Another layer of
complexity in interpretation is that most clinical studies are
in combination with chemotherapy agents, making it more
difficult to extract the effects of each VEGF inhibitor.
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